Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry represents a group of coagulation factors essential for blood clotting, excluding Fibrinogen (Factor I), Factor VIII, von Willebrand factor (vWF), and Factor XIII. These factors—II (prothrombin), V, VII, IX, X, XI, and XII—participate in the coagulation cascade, a series of enzymatic reactions leading to the formation of a stable blood clot. Deficiencies in these factors can lead to bleeding disorders, while their overactivation can contribute to thrombotic events. Many of these factors are serine proteases that activate downstream components in the cascade. Vitamin K is required for post-translational modification of Factors II, VII, IX, and X.
Various: Vitamin K antagonists inhibit post-translational modification of Factors II, VII, IX, and X. Heparin activates antithrombin, which inhibits several coagulation factors. DOACs directly inhibit specific factors like Factor Xa or Thrombin (Factor IIa).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coagulation Factors (excluding Fibrinogen, FVIII, vWF, FXIII) (Coagulation Factors (excl. I, VIII, vWF, XIII)).